Loonshots Summary and key ideas

Loonshots, by Safi Bahcall.

Loonshots are ideas or projects that are neglected, widely dismissed, and sometimes treated as evidence that their champion is unhinged. They differ from moonshots, ambitious goals already expected to matter. A loonshot is fragile because it lacks obvious support. Before success, it may look too strange, risky, or impractical for money, authority, or patience. Yet such ideas can drive breakthroughs that later seem inevitable.

The book's opening problem is a paradox. Lone inventors often carry unconventional ideas, but large groups must turn them into products or strategies that work. The same capable team that builds and delivers may reject an idea at its most vulnerable stage. Good teams can kill great ideas, and collective wisdom can become crowd tyranny when stakes are high. Breakthroughs usually pass through skepticism, not institutional celebration.

Bahcall makes the problem personal through cancer. He describes Alex, whose Kaposi's sarcoma had advanced after six chemotherapy regimens failed. Alex received a new cancer drug as a last resort and recovered after months of treatment. The author's father later developed aggressive leukemia and died despite expert advice and desperate efforts to find treatment. Cancer development has real obstacles: disrupted systems, poor laboratory predictions, long trials, and costs that can reach hundreds of millions. Bahcall accepts those explanations but says they are incomplete. Some candidates are buried by decisions, not only defeated by biology.

Richard Miller's drug shows the fragility. It was an irreversible binder, a “piranha,” that attacked an overactive protein rather than gently dialing it down. Its strength allowed a low dose, but if it attached to the wrong protein, it could not be washed out and might cause fatal toxicity. Some terminally ill patients understood and accepted the danger. Investors did not. Miller lost a boardroom battle and resigned; physicians continued the trial after reviewing laboratory results. In nearly four hundred patients, ibrutinib produced a nearly tenfold higher response rate than standard therapy. The trial stopped because withholding it from control patients seemed unethical, and the FDA approved it soon afterward. A large pharmaceutical company that had ridiculed the idea later acquired Miller's company for twenty-one billion dollars. The lesson is not that every risky idea deserves rescue. It is that important ideas often look unreasonable before evidence changes the balance.

Similar reversals appear elsewhere. Nokia moved from rubber and toilet paper to pioneering cellular phones and briefly became Europe's most valuable company. Yet leaders rejected an internet-ready touchscreen phone and app store developed by its engineers. Those ideas appeared in the iPhone; five years later Nokia had sold its mobile business and lost roughly a quarter trillion dollars in value. Merck and Disney show related patterns: Merck was long admired for medical research but later missed major breakthroughs, while Disney declined after The Lion King despite retaining much of its talent and desire to do excellent work. The mystery is why successful teams sometimes change behavior.

That question challenges the idea that large companies fail because their people are inherently conservative. The same people may support wild ideas in a startup. The setting matters because a group is not merely a collection of individuals. Its organization can create behaviors that no member displays alone, just as the phase of matter cannot be explained by one molecule. “More is different.” Nurturing a loonshot resembles a liquid-like phase, while developing a franchise, such as a sequel, resembles a solid-like phase. A group can shift between them.

Water changes phase when competing forces cross a threshold: binding pulls molecules toward rigid order, while entropy pushes toward disorder. Organizations have analogous incentives, loosely called stake and rank. Stake connects a person to the group's outcome; in a small biotech, success or failure may make participants heroes or cost them their jobs. Rank brings status, titles, and promotion-related pay. As a company grows, outcome stakes tend to shrink while rank benefits grow. When they cross, career position can matter more than an uncertain project. The group begins rejecting loonshots even though its members remain intelligent, hardworking, and well intentioned.

The transition cannot be eliminated, and one structure cannot preserve innovation forever. But understanding its forces may help manage its timing and effects; at the edge, elements of both phases can coexist. This is the book's governing problem: innovation is a systems problem involving fragile ideas, thresholds, incentives, and collective behavior. Sustaining a breakthrough requires managing the group's phase, not merely finding smart people.